News Conference News ACC 2024 BE ACTIVE: Gaming for Points and Money Can Boost Step Counts L.A. McKeown April 11, 2024
News Conference News Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality Michael O'Riordan March 22, 2024
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2023 Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH Michael O'Riordan May 26, 2023
News Conference News EAS 2023 High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture Michael O'Riordan May 23, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin Yael L. Maxwell March 13, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021